



بسم الله الرحمن الرحيم

∞∞∞∞

تم رفع هذه الرسالة بواسطة / سلوي محمود عقل

بقسم التوثيق الإلكتروني بمركز الشبكات وتكنولوجيا المعلومات دون أدنى

مسئولية عن محتوى هذه الرسالة.

ملاحظات: لا يوجد





# Assessment the Role of Non Invasive Biomarkers as an Early Predictors of Mucosal Healing in Ulcerative Colitis Patients Treated with the Biological Therapy

## Thesis

---

Submitted for Partial Fulfilment of  
Master Degree in Tropical Medicine

---

By

***Shaimaa Abdelrahman Ahmed***  
*M.B.B.Ch.*

Under supervision of

**Prof./ Ashraf Mohamed AL Breedy**  
*Professor of Tropical Medicine*

*Faculty of Medicine - Ain Shams University*

**Dr/ Mohamed Mahmoud Eltabbakh**

*Assistant Professor of Tropical Medicine*

*Faculty of Medicine - Ain Shams University*

**Dr/ Yasser Arafat Abd El Razek**

*Lecturer of Tropical Medicine*

*Faculty of Medicine - Ain Shams University*

Faculty of Medicine  
Ain Shams University  
2022

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببنا نك لا علم لنا  
إلا ما علمتنا إنك أنت  
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

# Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**,  
the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof./ Ashraf Mohamed AL Breedy**, Professor of Tropical Medicine - Faculty of Medicine- Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr/ Mohamed Mahmoud Eltabbakh**, Assistant Professor of Tropical Medicine, Faculty of Medicine, Ain Shams University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr/ Yasser Arafat Abd El Razek**, Lecturer of Tropical Medicine, Faculty of Medicine, Ain Shams University, for his great help, active participation and guidance.*

*I would like to express my hearty thanks to all my family for their support till this work was completed.*

*Last but not least my sincere thanks and appreciation to all patients participated in this study.*

**Shaimaa Abdelrahman Ahmed**

# List of Contents

Title	Page No.
List of Tables .....	i
List of Figures .....	iii
List of Abbreviations.....	v
Introduction .....	1
Aim of the Work.....	5
Review of Literature	
Ulcerative Colitis (UC) .....	6
Non invasive biomarkers in IBD .....	41
Patients and Methods.....	56
Results .....	64
Discussion .....	99
Summary .....	116
Conclusion .....	120
Recommendations .....	121
References .....	122
Arabic Summary	

# List of Tables

Table No.	Title	Page No.
Table (1):	Disease activity adapted from Truelove and Witts.....	14
Table (2):	Mayo activity scoring index .....	15
Table (3):	Mayo activity scoring index.....	59
Table (4):	Baseline characteristics of the studied patients.....	64
Table (5):	Baseline laboratory data of the studied patients before starting biological therapy .....	66
Table (6):	Disease severity and other studied parameters among the studied patients before starting biological therapy: .....	68
Table (7):	Response to steroids, extraintestinal manifestations, timing of starting biological treatment and type of biological therapy .....	70
Table (8):	Laboratory parameters at 3 months follow up from starting biological therapy:.....	73
Table (9):	Disease severity at 6 months follow up from starting biological therapy:.....	75
Table (10):	Laboratory parameters at 6 months follow up from starting biological therapy:.....	76
Table (11):	Mayo endoscopic scores, response to biological therapy and mucosal healing at 6 months follow up.....	78
Table (12):	Laboratory data at baseline, 3 months, 6 months from starting biological therapy: .....	81
Table (13):	The studied ratios (NLR, PLR, LMR, PMR and CRP to albumin) at baseline, 3 months, 6 months from starting biological therapy: .....	82

# List of Tables **cont...**

Table No.	Title	Page No.
<b>Table (14):</b>	Relation of mucosal healing at 6 months with different parameters: .....	89
<b>Table (15):</b>	Relation of mucosal healing at 6 months with non-invasive markers at baseline of the studied patients:.....	90
<b>Table (16):</b>	Relation of mucosal healing at 6 months with non-invasive markers at 3 and 6 months follow up of the studied patients: .....	92
<b>Table (17):</b>	Relation between clinical response at 6 months and studied ratios at baseline:.....	94
<b>Table (18):</b>	Relation between clinical remission at 6 months and the studied ratio at baseline:.....	95
<b>Table (19):</b>	Relation between clinical response, clinical remission and mucosal healing:.....	96
<b>Table (20):</b>	The best ratios to predict mucosal healing at 6 months.....	97

# List of Figures

Fig. No.	Title	Page No.
<b>Figure (1):</b>	Schematic representation of the interaction between $\alpha 4\beta 7$ integrin and vedolizumab.....	33
<b>Figure (2):</b>	Sex distribution among the studied patients.....	65
<b>Figure (3):</b>	Occupation of the studied patients.....	65
<b>Figure (4):</b>	MES of the studied patients.....	69
<b>Figure (5):</b>	Location of the disease of the studied patients.....	69
<b>Figure (6):</b>	Response to steroids among the studied patients.....	71
<b>Figure (7):</b>	Extraintestinal manifestations among studied patients.....	71
<b>Figure (8):</b>	Type of biological therapy among the studied patients.....	72
<b>Figure (9):</b>	Disease severity after 6 months follows up among the studied patients.....	75
<b>Figure (10):</b>	Mayo endoscopic score at 6 months follow up.....	79
<b>Figure (11):</b>	Mucosal healing at 6 months follow up.....	79
<b>Figure (12):</b>	Clinical response to biological therapy at 6 months follow up.....	80
<b>Figure (13):</b>	Lymphocyte and monocyte counts at baseline, 3months and 6 months from starting biological therapy.....	84
<b>Figure (14):</b>	Lymphocyte to monocyte ratio at baseline, 3months and 6 months from starting biological therapy.....	84



# List of Figures (Cont...)

Fig. No.	Title	Page No.
<b>Figure (15):</b>	Neutrophil to lymphocyte ratio at baseline, 3months and 6 months from starting biological therapy .....	85
<b>Figure (16):</b>	Platelet count at baseline, 3 months and 6 months from starting biological therapy.....	85
<b>Figure (17):</b>	Platelet to lymphocyte ratio at baseline, 3 months and 6 months from starting biological therapy .....	86
<b>Figure (18):</b>	Platelet to monocyte ratio at baseline, 3 months and 6 months from starting biological therapy .....	86
<b>Figure (19):</b>	ESR values at baseline, 3 months and 6 months from starting biological therapy.....	87
<b>Figure (20):</b>	CRP values at baseline, 3 months and 6 months from starting biological therapy.....	87
<b>Figure (21):</b>	CRP to albumin ratio at baseline, 3 months and 6 months from starting biological therapy .....	88
<b>Figure (22):</b>	ROC Curve analysis to assess the best cut off point of the studied ratios.....	98

# List of Abbreviations

Abb.	Full term
<i>5ASA</i>	<i>Aminosalicylates</i>
<i>6-MP</i>	<i>6-mercaptopurine</i>
<i>ADA</i>	<i>Adalimumab</i>
<i>ANCA</i>	<i>Antineutrophil cytoplasmic antibodies</i>
<i>ASCA</i>	<i>Anti- <i>Saccharomyces cerevisiae</i> antibodies</i>
<i>AXR</i>	<i>Abdominal x ray</i>
<i>AZA</i>	<i>Azathioprine</i>
<i>B2-M</i>	<i>Beta 2 microglobulin</i>
<i>BE</i>	<i>Barium enema</i>
<i>BUS</i>	<i>Bowel ultrasound</i>
<i>CD</i>	<i>Crohn's disease</i>
<i>CRP</i>	<i>C-reactive protein</i>
<i>CRP/ALB</i>	<i>C-reactive protein/albumin ratio</i>
<i>CsA</i>	<i>Cyclosporine</i>
<i>CTC</i>	<i>CT colonography</i>
<i>CTE</i>	<i>CT enterography</i>
<i>ECCO</i>	<i>European Crohn and Colitis Organization guidelines</i>
<i>EH</i>	<i>Endoscopic healing</i>
<i>ERCP</i>	<i>Endoscopic retrograde cholangiopancreatogram</i>
<i>ESR</i>	<i>Erythrocyte sedimentation rate</i>
<i>FC</i>	<i>Fecal calprotectin</i>
<i>IBD</i>	<i>Inflammatory bowel disease</i>
<i>IFX</i>	<i>Infliximab</i>
<i>IL-8</i>	<i>Interleukin-8</i>
<i>IQR</i>	<i>Inter-quartile range</i>
<i>MCS</i>	<i>Mayo clinic score</i>
<i>MES</i>	<i>Mayo endoscopic score</i>
<i>MH</i>	<i>Mucosal healing</i>

# List of Abbreviations (Cont...)

Abb.	Full term
<i>MRCP</i> .....	<i>Magnetic Resonance cholangio pancreaticography</i>
<i>MRI</i> .....	<i>Magnetic Resonance Imaging</i>
<i>NLR</i> .....	<i>Neutrophil-to-lymphocyte ratio</i>
<i>NLR</i> .....	<i>Neutrophil-to-lymphocyte ratio</i>
<i>NSAID</i> .....	<i>Non-steroidal anti-inflammatory drug</i>
<i>PLR</i> .....	<i>Platelet-to-lymphocyteratio</i>
<i>PMBCs</i> .....	<i>Peripheral blood mononuclear cells</i>
<i>QOL</i> .....	<i>Quality of life</i>
<i>RA</i> .....	<i>Rheumatoid arthritis</i>
<i>ROC</i> .....	<i>Receiver operating characteristic curve</i>
<i>TNF<math>\alpha</math></i> .....	<i>Tumor necrosis factor alpha</i>
<i>UC</i> .....	<i>Ulcerative colitis</i>
<i>VTE</i> .....	<i>Venous thromboembolism</i>
<i>WBC</i> .....	<i>White blood cells</i>

## INTRODUCTION

The inflammatory bowel disease (IBD) comprises two types, namely, the ulcerative colitis (UC) and Crohn's disease (CD). They are a spectrum of chronic idiopathic autoimmune inflammatory disorders with remission and relapses, primarily affecting the gastrointestinal system (*Machado et al., 2013*).

IBD occur with different frequencies around the world. The countries reporting for the highest incidence of UC are the United States, the United Kingdom and Sweden, IBD have always seemed to be rare in the Middle East and Northern Africa. No accurate registry of patients had ever studied the exact prevalence of CD and UC in these populations. In Mediterranean countries, the prevalence of UC was estimated to be 5/100000 in urban areas (*Matsuoka et al., 2018*).

UC is characterized by confluent mucosal inflammation and erosions starting from the anal verge and extending to a variable extent, where patients often complain of diarrhea associated with rectal bleeding, abdominal tenderness, and weight loss (*El-Atrebi et al., 2021*).

Etiopathogenesis of IBD comprises genetic components, environmental factors, microbial flora of the gut, and immune responses. However, the main mechanism seems to be the bacterial antigens gaining access to the antigen-presenting cells

through the impaired epithelial barrier (*Ordás and Eckmann, 2012*).

Ulcerative colitis (UC) is characterized by a neutrophil-mediated inflammation of the gut. Indeed, European Crohn and Colitis Organization guidelines (ECCO) have highlighted how the grade of neutrophilic infiltration is necessary for the diagnosis of this pathological condition and for the evaluation of histological activity (*Sandborn et al., 2015*).

Thus, colonoscopy is necessary to collect mucosal biopsies and assess neutrophilic infiltration for the diagnosis and during follow-up to evaluate treatment response and predict long-term outcome, although histological healing is still debated. However, colonoscopy is an invasive, costly, and not always well-tolerated examination for patients (*Mumolo et al., 2018*).

Apart from endoscopic interventions, disease severity can be also assessed using less-invasive biomarkers, including blood count, ESR, CRP and fecal calprotectin (*Alexander et al., 2007*).

In fact, systemic inflammation is characterized by a change in the levels of circulating white blood cells (WBC), and in particular it induces an increase in circulating neutrophils that is accompanied by a relative decrease in the percentages of lymphocytes (*Gökmen et al., 2015*).

In this regard, an increasing body of evidence has suggested that the neutrophil-to-lymphocyte ratio (NLR) can be a useful biomarker of many systemic inflammation responses and in the oncologic setting (*Goodman et al., 2015*).

There is also some evidence of a possible role of this simple biomarker in the UC setting, in particular concerning disease severity, but no sufficient studies have tested the value of this parameter in predicting therapeutic response to medical treatment (*Torun et al., 2012*).

Furthermore, the platelet-to-lymphocytes ratio (PLR) has recently been correlated to the prognosis of malignancies and to disease activity in rheumatologic diseases, but data on its role in UC patients are lacking (*Zhang et al., 2018*).

Medical therapy of IBD is complex as the disease etiology is multifactorial and the primary aim of pharmacotherapy is to dampen the generalized inflammatory response, thereby relieving symptoms. The specific goals of treatment in IBD include the control of acute exacerbation, maintenance of remission, treatment of specific complications, and surveillance of malignant transformation (*Brunton et al., 2018*).

Many drugs are used in the treatment of IBD including mesalamine derivatives, glucocorticoids and immunomodulators, in addition to the biologics that are derived partly or completely

from living biological sources such as animals and humans (*D'Haens and Sartor, 2014*).

The most widely used biologics are the TNF- $\alpha$  inhibitors such as adalimumab, certolizumab, golimumab, and infliximab, which are highly effective in the treatment of both UC and CD. The other biological agents in IBD include the integrin receptor antagonists, namely, vedolizumab and natalizumab, and IL-12 and IL-23 antagonist (Ustekinumab) (*Chan et al., 2017*).